DocuSign stock tanks 18% after company cuts billings outlook

DocuSign shares plummeted 18% after the company reported better-than-expected Q1 earnings, with EPS at $0.90 versus the expected $0.81 and revenue at $764 million versus the expected $748 million. However, the stock decline was triggered by lowered full-year billings guidance, now projected at $3.28 billion to $3.34 billion, down from the previous $3.3 billion to $3.35 billion, despite an announced $1 billion increase to its stock buyback program.

Analysis

DocuSign (DOCU) experienced a significant 18% share price decline despite reporting fiscal first-quarter earnings per share of 90 cents, exceeding analyst expectations of 81 cents, and revenue of $764 million, which surpassed the $748 million forecast. The primary driver for the negative market reaction was the company's billings performance and outlook; fiscal first-quarter billings of $739.6 million fell short of both analyst estimates ($746 million) and DocuSign's own guidance ($741-$751 million). Compounding this, the company revised its full-year billings forecast downwards to a range of $3.28 billion to $3.34 billion, from a prior $3.3 billion to $3.35 billion. Despite these billings concerns, DocuSign demonstrated underlying strength with an 8% year-over-year increase in both total revenue and subscription revenue, reaching $764 million and $746.2 million respectively for the quarter. Net income also showed substantial improvement, rising to $72.1 million from $33.8 million a year earlier. Looking ahead, DocuSign's revenue guidance for the fiscal second quarter ($777-$781 million) and the full fiscal year ($3.15-$3.16 billion) slightly exceeded consensus estimates. Concurrently, the company announced an expansion of its share repurchase program by an additional $1 billion, bringing the total authorization to $1.4 billion, signaling confidence in its value or an attempt to support the stock price amidst the guidance cut.

Key Decisions for Investors

• Investors should closely monitor DocuSign's billings trends in subsequent quarters, as this metric has become a focal point for valuation following the revised guidance.
• The significant share price correction warrants a re-evaluation of risk-reward, especially considering the otherwise solid Q1 earnings beat, positive Q2 and full-year revenue outlook, and the enhanced $1.4 billion share repurchase program.
• Consideration should be given to whether the market's sharp negative reaction to the billings outlook overshadows the company's profitability, continued revenue growth, and commitment to capital returns.